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“It is characteristic of science and progress that they continually open new fields to 
our vision.” Louis Pasteur, the famous French microbiologist, spoke those words 
more than a hundred years ago, during the first “Golden Age” of microbiology. At 
that time, through the introduction of culture media, sterile technique, and new 
staining methodologies, Pasteur, Koch and others, proved that microorganisms 
caused many of the devastating diseases that had ravaged civilization over the 
millenia. Within a few short years of their discoveries, centuries-old traditions and 
beliefs, which held that diseases were transmitted by some peculiar miasmas, quickly 
fell into disfavor. All of the possible applications of the new technology were not 
apparent at the time, but many of the more far-sighted individuals, Pasteur among 
them, realized that they were at a watershed moment in human history. The incred­
ible improvements in the health and life span of humans over the last hundred years 
attest to their vision.
Contemporary visionaries contend that we are currently poised at another great 
moment in medical history. The identification of DNA as the hereditary material and 
the deciphering of the genetic code provided the prologue for the current Golden 
Age. The subsequent development of new technologies, which allow scientists to 
identify, characterize, and manipulate specific genes and to track the distribution and 
movement of other molecules within cells, provide the tools that will be used to 
complete the revolution. And although it is difficult to predict the specific outcome of 
these current scientific and technologic breakthroughs, one result does seem certain - 
betterment of the human condition.
CDC is actively engaged in the practical applications of this explosion of new 
technology to disease problems through a Congressional mandate. Until 1986, the 
principal methods used by the Centers for Disease Control (CDC) to transfer technol­
ogy outside the Government were training, education, and information dissemina­
tion. In 1986, Congress passed the Federal Technology Transfer Act of 1986 to 
improve the link between the Federal laboratories’ technology base and U.S. busi­
nesses. This law and subsequent Executive Order 12591 (April 10, 1987) authorize 
Federal laboratories to patent and exclusively license inventions to and collaborate 
with businesses on research and development.
The enclosed abstracts address the research in the application of increasingly 
complex technology to diagnostics. The application of basic research leads to im­
proved diagnostic tools which in turn enhances epidemiology.
If you would like additional information on the above or information on CDC’s 
cooperative research policies and procedures, please contact either:
Dr. Joseph McDade or R. Eric Greene
Associate Director for Technology Transfer Coordinator
Laboratory Science Centers for Disease Control
Center for Infectious Diseases 1600 Clifton Road; Mailstop A20
Centers for Disease Control Atlanta, GA 30333
1600 Clifton Road; Mailstop C12 (404)639-3812
Atlanta, GA 30333
(404) 639-3967
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ADVANCES IN VACCINE DEVELOPMENT FOR ENCAPSULATED 
BACTERIA.
Claire V. Broome, Jay Wenger, Balasubr Swaminathan, and George M. Carlone, 
Meningitis and Special Pathogens Branch, Division o f Bacterial Diseases
Serum antibodies directed against the polysaccharide capsule of bacteria responsible 
for meningitis and sepsis are capable of protecting against human disease. However, 
infants who are at highest risk of disease are unable to respond to polysaccharide 
antigens. Recent research has shown that covalently linking the polysaccharide to a 
protein carrier is effective in eliciting antibody in infants. Trials are currently under 
way to evaluate clinical protection induced by four different Haemophilus influenza  
type b conjugate vaccines. Our work focuses on the performance of conjugate vac­
cines, variables that might affect immunogenicity in different conjugates, and poten­
tial applications for this technology in development of vaccines for other high prior­
ity diseases such as Neisseria Meningitidis, group B streptococcus, and the 
pneumococcus.
BACTERIAL ISOPRENOID QUINONE STRUCTURE DETERMINATION.
George M. Carlone and Susan H. Turner, Meningitis and Special Pathogens 
Branch, Division o f Bacterial Diseases
The chemical structure of novel class of methyl-substituted menaquinones (2,[5 or 
8]-dimethyl-3-farnesyl-farnesyl-l,4-naphthoquinone) was determined using ultravio­
let and mass spectroscopy and nuclear magnetic resonance analysis. Quinones are 
useful markers for taxonomic and epidemiologic groupings since they are widely 
distributed, structurally diverse, and physiologically significant. Isoprenoid quinones 
of bacteria are lipophilic components of the cytoplasmic membrane that play impor­
tant roles in the transfer of electrons in the respiratory chain and function in oxidative 
phosphorylation and active transport. Determination of the quinone composition in 
the electron transport chain defines the membrane-associated energy transduction 
potential of a given bacterial species. The class of quinone and the length and degree 
of saturation on the isoprenoid side chain are useful in bacterial taxonomy.
„ BACULOVIRUS-EXPRESSED ANTIGENS FOR HERPESVIRUS 
SERODIAGNOSTIC TESTS.
Demetrio Sanchez-Martinez and Philip E. Pellett, Viral Exanthems and Herpesvi­
rus Branch, Division o f Viral and Rickettsial Diseases
Herpes simplex virus type 1 (HSV-1) glycoprotein G (gG-1) and its HSV-2 counterpart 
(gG-2) are type-specific antigens that allow serologic discrimination of prior infection 
with HSV-1 from prior infection with HSV-2. Epstein-Barr virus (EBV) specifies a 
glycoprotein, gpllO , which is the basis of a sensitive EBV-specific serologic test. The 
utility of assays based on these proteins has been limited by the difficulty of prepar­
ing large amounts of the purified antigens. We have expressed these antigens in a 
baculovirus gene expression system using a novel transfer vector that mimics the 
nucleotide sequence of the wild-type baculovirus polyhedrin gene 5’ nontranslated 
region, and allows construction of recombinant viruses differing from the wild-type 
baculovirus only in the coding sequence of the gene to be expressed. The level of 
expression using this vector is higher than that obtained using a vector containing 
extraneous nucleotides in the polyhedrin 5’ non-coding sequence. The baculovirus- 
expressed proteins are recognized by human serum specimens, the reactions with 
gG-1 and gG-2 being HSV type-specific.
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.  CD4 AND HIV: ANALYSIS OF BINDING SITE INTERACTIONS AND 
POTENTIAL FOR THERAPEUTICS.
/. Steven McDougal, Alison Mawle, Janet Nicholson, Thomas Hodge, Sherry Orloff, 
and M. Susan Kennedy, Immunology Branch, Division o f Immunologic, Oncologic, 
and Hematologic Diseases
CD4 is a cell surface protein found at highest density on a subset of T lymphocytes 
and at lower density on other hematopoietic cells such as macrophages. CD4 T cells 
perform critical antigen recognition and helper/inducer functions. CD4 has also been 
shown to function as a receptor for HIV-1. The CD4 gene was first cloned and 
sequenced by Maddon et al. In collaboration with this group, we have been involved 
in genetic manipulations of CD4 and its expression in various cellular environments. 
In one such manipulation, introduction of a stop codon at the extracellular- 
transmembrane junction of CD4 cDNA and expression of the construct in mamma­
lian cells resulted in a secreted form of soluble CD4 (sCD4). sCD4 binds to HIV-1 
envelope glycoprotein, blocks HIV-1 binding to CD4 T cells, and effectively inhibits 
HIV-1 infectivity for T cells and macrophages in vitro. sCD4 is now in phase I/II 
clinical trials. Physicochemical studies and mapping studies with truncated and 
mutagenized forms of sCD4 have further localized the binding site of HIV-1 and its 
structural constraints. Such studies may facilitate the design of more effective (second 
generation) constructs of CD4 that prolong half-life, increase valence, or change 
affinity, or that deliver toxins, drugs, or mediator molecules to virus-infected cells.
* DETECTION AND CHARACTERIZATION OF HEPATITIS A VIRUS 
(AND OTHER FASTIDIOUS VIRUSES) BY IMMUNOSELECTION AND 
ENZYMATIC AMPLIFICATION OF NUCLEIC ACID.
Betty Robertson, Omana Nainan, Bhaiona Khanna, Vicki K. Brown, and Harold S.
Margolis, Hepatitis Branch, Division o f Viral and Rickettsial Diseases
Polymerase chain reaction (PCR) amplification of nucleic acid present in clinical, 
environmental, or fomite-derived samples is a highly sensitive method for detection 
of infectious viral agents that cannot be identified by traditional cell culture ap­
proaches. However, the inherent character of these types of samples introduces a 
multitude of potential problems which complicate amplification and analysis. Using 
hepatitis A virus (HAV) as a model, we have approached the detection and identifi­
cation of wild-type viruses in clinical specimens by an initial antibody capture of 
virus prior to PCR amplification. Immunocapture of virus with specific antibody 
followed by reverse transcription, PCR amplification, and traditional hybridization 
techniques results in the detection of between 30 and 300 infectious viral particles, 
while the use of a 5’ end-labeled primer during the PCR reaction increases sensitivity 
of detection by approximately one log. The primer pair used for amplification was 
selected to bind relatively conserved sequences which flank a variable region within 
the VPl coat protein, and has resulted in the amplification and detection of HAV 
agents that differ genetically by 20-25%. The use of these approaches can be applied 
to detect virus within potentially infected foods or other environmental sources of 
HAV contamination.
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DEVELOPMENT AND EVALUATION OF ENZYME-LINKED 
s IMMUNOSORBENT ASSAYS FOR DETECTION OF SHIGA-LIKE 
TOXIN I AND SHIGA-LIKE TOXIN II.
Frances P. Downes, James H. Green, Katherine Greene, Nancy Strockbine, joy G.
Wells, and I. Kaye Wachsmuth, Enteric Diseases Branch, Division o f Bacterial
Diseases
Shiga-like toxin (SLT)-producing Escherichia coli have been associated with a spec­
trum of human illnesses, including hemorrhagic colitis, hemolytic uremic syndrome 
(HUS), and thrombotic thrombocytopenic purpura (TTP), as well as with edema 
disease in swine. Two antigenically distinct groups of toxins designated SLT-I and 
SLT-II have been identified. We have developed two sandwich enzyme-linked immu­
nosorbent assays (ELISAs) based on two toxin-specific antibodies: a monoclonal 
capture antibody and a rabbit polyclonal second antibody. When compared with the 
conventional cytotoxicity neutralization assay, the ELISAs were 100% sensitive and 
specific for identifying moderate to high-level SLT-producing E. coli among 166 
human and 54 animal isolates tested. Early diagnosis of SLT-producing E. coli 
infections is important in controlling person-to-person transmission in outbreak 
situations and in monitoring infected individuals for development of HUS or TTP. 
The SLT ELISAs provide an attractive alternative to cell culture for identifying these 
organisms and should facilitate epidemiologic studies of SLT-producing E. coli asso­
ciated with human and animal infections.
DIAGNOSIS OF NEW HUMAN RETROVIRUSES.
Tom M. Folks, Retrovirus Diseases Branch, Division o f Viral and Rickettsial Dis­
eases
Detection and isolation of new and unknown human retroviruses from clinical 
material will depend on an understanding of the target cell type in which the agent 
replicates. Modification of the cell may be needed to make it permissive to virus 
infection and replication in vitro. Currently we are developing methods for cytokine 
and cell membrane perturbation which “activate” retroviruses from latent states. 
Following cellular activation, culture supernatants containing putative retroviruses 
are concentrated, solubilized, and reverse transcribed. The resultant cDNA is ampli­
fied by polymerase chain reaction (PCR) using “consensus” primers from known 
mammalian retroviral genes (LTR, GAG, POL). The amplified products are then 
directly sequenced for known retroviral sequences or used as molecular probes. The 
combined technologies of recombinant cytokine cellular modification and PCR 
should provide new capabilities for identifying retroviral agents from diseases of 
unknown etiology.
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EXPRESSION OF INFLUENZA A AND B NUCLEOPROTEIN ANTIGENS IN 
~  BACULOVIRUS.
Paul A. Rota, Renee A. Black, Barun K. De, and Alan P. Kendal, Influenza Branch, 
Division o f Viral and Rickettsial Diseases
Full-length cDNA clones of the nucleoprotein (NP) genes of influenza A/Ann Arbor/ 
6/60 and B/Ann Arbor/1/86 viruses were constructed from virion RNA and subse­
quently expressed in Spodoptera frugiperda (Sf9) cells using the baculovirus vector, 
Autographa californica nuclear polyhedrosis virus (AcNPV). Western blot analysis of 
lysates prepared from Sf9 cells infected with the recombinant viruses confirmed that 
the baculovirus-expressed NP antigens were reactive with monoclonal antibodies 
specific for either type A or B NP and with anti-NP antibodies in human serum 
samples. Electrophoretic analysis indicated that the expressed influenza NP antigens 
comigrated with NP purified from influenza A or B virions and that the recombinant 
NP antigens represented greater than 10% of total protein in infected cells. Dilutions 
of clarified Sf9 cell lysates were used as antigens in a standard enzyme immunoassay 
format to detect serum antibody specific for influenza A or B viruses. The results 
from assays using the baculovirus-expressed NP antigens showed close correlation 
with the results obtained using bacterially-expressed NP antigen as well as comple­
ment fixation. Therefore, baculovirus-expressed NP antigens could potentially be 
used to develop a standardized assay system for the serodiagnosis of influenza virus 
infections as a more convenient alternative to existing methods.
v GENERATION, IDENTIFICATION, AND ISOLATION OF BISPECIFIC 
MONOCLONAL ANTIBODIES.
Edwin W. Ades, Carolyn Dawson*, Janet Nicholson*, and J. Todd Parker, Biolog­
ical Products Branch, Scientific Resources Program, and Immunology Branch, 
Division o f Immunologic, Oncologic, and Hematologic Diseases*
Enhanced tumor targeting, by cross-linking effector to target cells, has been previ­
ously demonstrated by several investigators using bispecific antibodies. Hybrid- 
hybridomas are selected via two-color intracellular fluorescent dyes (rhodamine 123 
and dihydroethidium), isolation of the two-color fusion population is accomplished 
by fluorescence-activated cell sorting (FACS), and analysis of the fusion efficiency is 
performed. Antibody targeting specificity is examined using FACScan analysis of the 
respective treated target cells. The lytic efficacy of our bispecific antibody (anti­
melanoma x anti-CD3) is examined both in vitro and in vivo following treatment with 
bispecific antibody. A higher melanoma lytic response following treatment with our 
bispecific antibody, in comparison with treatment with either parental monoclonal 
antibody, has been demonstrated. This provides new opportunities for adoptive 
immunotherapy and identifying new anti-proliferative activities for these antibodies.
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GENETIC ENGINEERING IN MAMMALIAN CELLS: VEHICLES FOR GENE 
TRANSFER.
Edwin W. Ades, Francisco Candal, and Debra Musgrove, Biological Products 
Branch, Scientific Resources Program
Mammalian cells will express exogenously introduced genes provided that the genes 
possess the proper DNA regulatory elements recognized and used by the host cell. 
The yield of protein product from an introduced gene can be increased by several 
means; one is to increase the actual number of DNA copies of the gene within each 
cell (gene amplification), another is to use control sequences that may respond to 
external signals. Our goal is to introduce a gene into a mammalian cell under the 
control of an inducible promoter. Large scale growth of mammalian cells that require 
long-term cell viability prior to external signal has been established as well as protein 
products. These cells may be a suitable cellular vehicle for the introduction and 
control of therapeutic genes into patients.
x HUMAN-RODENT HYBRID CELLS AS A MODEL FOR FACTORS THAT 
REGULATE HUMAN RETROVIRUS EXPRESSION.
Clyde Hart, Judith Galphin, Chin-Yih Ou, and Gerald Schochetman, Laboratory
Investigations Branch, Division o f HIV/AIDS
Human retroviruses contain nonstructural regulatory genes that control viral expres­
sion in an infected host cell. In many instances these regulatory genes are believed to 
work in concert with or induce expression of host cell factors to effect virus produc­
tion and pathogenesis. To investigate the human-specific host cell factors involved in 
regulating expression of the retrovirus HIV, human-Chinese hamster ovary hybrid 
cells with defined sets of human chromosomes were assayed by DNA transfection. 
High levels of virus production and viral trans-activator gene-induced activation of 
the viral long terminal repeat (LTR) was present only in cells containing human 
chromosome 12. High levels of trans-activation of the LTR from HTLV I and II 
retroviruses, however, was not supported by hybrid cells containing human chromo­
some 12. This indicates that the regulatory genes of diverse human retroviruses 
require different host cell factors to support elevated gene expression. Identification 
of specific host cell factors involved in the retroviral disease process may provide 
new targets for the development of antiviral therapy.
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HUMAN IMMUNE RESPONSES TO ONCHOCERCA VO LVU LU S: 
POSSIBLE RELATIONSHIP BETWEEN SPECIFIC ISOTYPIC REACTIVITY 
TO ANTIGENS AND STATE OF IMMUNITY.
Ann E. Boyer, Victor C. Tsang, Mark L. Eberhard, Joy A. Brand, Wei Zhou, and
Laureen Laughnan, Parasitic Diseases Branch, Division o f Parasitic Diseases
Onchocerciasis, a leading cause of human blindness, affects an estimated 20-50 
million persons. Isotypic differences in immune responses to Onchocerca volvulus 
antigens were assessed for 798 persons residing in endemic-disease Guatemalan 
areas by falcon assay screening test enzyme-linked immunosorbent assay (FAST- 
ELISA) and immunoblot (western blot). The population was separated into four 
groups based on clinical status: N + /-F + , N + F-, N-F-H + , and N-F-H-, where N = 
nodule (adult O. volvulus), F = microfilaria, and H = history. Isotope quantification 
by FAST-ELISA showed that IgGl reactivity to O. volvulus-specific antigens was 
predominant in the majority of infected persons and was from 3 to 5 times lower in 
putatively “immune” persons. Immunoblots showed frequent reactivity to a group of 
glycoproteins at 20 kilodaltons by IgG3 in most uninfected persons from 
hyperendemic-disease areas and in some N + F- persons. Conversely, in most F + 
persons, reactivity to this antigen was by IgGl and not by IgG3. On immunoblot, a 
mangabey inoculated with L3s of O. volvulus began to recognize GP20 at 2 weeks 
post-inoculation. At this early date, antigen recognition was presumably elicited by 
the L3 stage , suggesting that GP20 may be a common adult/larval stage antigen. The 
fact that GP20 is predominantiy recognized by IgG3 in uninfected persons and some 
amicrofilaremic persons suggests that IgG3 activity to GP20 may be associated with 
acquired immunity and offers a potential target antigen for vaccine development.
v. HYBRIDIZATION PROTECTION ASSAY FOR RAPID AND SENSITIVE 
DETECTION OF NUCLEIC ACIDS.
Chin-Yih Ou, Laboratory Investigations Branch, Division o f HIV/AIDS
Nucleic acid amplification via polymerase chain reaction (PCR) is widely used in the 
detection and quantification of genetic information in various genetic defects and 
infectious agents including human immunodeficiency virus. Current methods for the 
detection of the amplified DNA are time-consuming, labor-intensive, and often in­
volve radioisotopic oligonucleotide probes. To overcome these drawbacks, we have 
applied a hybridization protection assay (HPA) using chemiluminescent acridinium 
ester (AE)-labeled, single-stranded oligonucleotide probes. The AE groups on the 
unhybridized probe are highly sensitive to alkaline hydrolysis but are resistant when 
the probe is hybridized with the amplified DNA. Thus simple alkaline hydrolysis can 
selectively remove the AE on unhybridized probe in the hybridization solution 
without physical separation as required for other detection methods such as gel 
electrophoresis and blotting. The quantity of the remaining AE on the hybridized 
probe is measured by a luminometer. The sensitivity of HPA is comparable to that of 
the 32P-labeled probes. The assay offers a rapid (1 hour), quantitative, and highly 
reproducible measure of PCR-amplified DNA.
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IDENTIFICATION OF EPITOPES IN THE P24 (GLYCOSAMINOGLYCAN) 
n PROTEIN OF HIV-1 THAT ELICIT A CYTOTOXIC T LYMPHOCYTE 
RESPONSE IN INFECTED PERSONS.
Alison C. Mawle and J. Steven McDougal, Immunology Branch, Division o f Hema­
tologic, Oncologic, and Immunologic Diseases
We have studied the cytotoxic T lymphocyte (CTL) response to the p24 (glycosami- 
noglycan) antigen in long-term survivors from a San Francisco cohort of persons who 
have been HIV-1 seropositive and completely asymptomatic for an average of 9 years. 
This group was compared with a group of AIDS patients from the same cohort who 
had also been infected for an average of 9 years. The assay was performed using 
freshly isolated peripheral blood lymphocytes (PBL) as effector cells, and autologous 
Epstein-Barr virus-B (EBV-B) cells infected with a p24 vaccinia construct were used 
as target cells. We have shown that persons who are asymptomatic have a CTL 
response to p24 that is major histocompatibility complex-restricted, whereas persons 
with AIDS have no response to p24.
We have a panel of nine peptides derived from p24 that are potential T cell epitopes, 
and we are using these to determine important epitopes in this response. Freshly 
isolated PBL will be assayed for CTL activity on autologous EBV-B cells pulsed with 
each peptide. We hope to identify a series of peptides that will act as CTL targets in 
conjunction with the major HLA determinants in the population, and which therefore 
could be used as the basis of a vaccine. We plan to try various techniques using these 
peptides to stimulate CTL in both mouse and primate models.
IDENTIFYING DIVERSE MICROBES WITH CERTAIN WELL-CONSERVED 
GENES: POLYMERASE CHAIN REACTION/RESTRICTION FRAGMENT 
LENGTH POLYMORPHISM AS APPLIED TO RICKETTSIAE.
Russell Regnery, Catherine Spruill, M. Drancourt, and Brian D. Plikaytis, Division 
o f Viral and Rickettsial Diseases, Statistical Services Activity, Viral and Rickettsial 
Zoonoses Branch, Division o f Bacterial Diseases
We have developed a novel, simple, and fast method for differentiation of various 
species and genotypes of rickettsiae. Polymerase chain reaction amplification of 
specific gene(s), using well conserved “universal” primer sequences, was used to 
produce DNA products from all rickettsiae tested. This amplified DNA was subjected 
to restriction-endonuclease digestion and analysis on polyacrylamide gels. These 
digests produced diagnostic, species-specific patterns; isolates from clinical samples 
were readily identified in this manner. Divergence between the genes of various 
species can also be estimated. These methods should be applicable to a wide variety 
of bacteria.
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ISOLATION AND PURIFICATION OF A SPECIES-SPECIFIC 
STREPTO C O CC U S PN EU M O N IAE  PROTEIN ANTIGEN BY 
ISOELECTRIC FOCUSING.
Harold Russell and Jean A. Tharpe, Respiratory Disease Branch, Division of
Bacterial Diseases
Streptococcus pneumoniae is a leading cause of morbidity and mortality in the 
United States and developing countries. Except for detection of antigen in cerebrospi­
nal fluid, existing antigen and antibody tests have not proved to be diagnostically 
useful because of low sensitivity and specificity. A new species-specific protein 
isolated from S. pneumoniae has been purified to electrophoretic homogeneity by 
isoelectric focusing. The protein has a molecular mass of 37 kilodaltons (kDa) and a 
pi of 5.2. Monoclonal antibodies to the 37-kDa antigen do not react with 62 other 
strains representing 15 genera that may also cause lower respiratory diseases. The 
monoclonal antibodies reacted with all capsular types of S. pneumoniae tested (N = 
21). The effectiveness of the purified 37-kDa antigen as a useful immunodiagnostic 
marker for the etiologic diagnosis of infection is under study.
MAINTENANCE OF VIRAL LATENCY AND REGULATION OF VIRAL GENE 
EXPRESSION: DETECTION OF VIRUS BY IN VIVO FOOTPRINTING.
Daniel P. Bednarik, Patricia C. Guenthner, Nora J. Besansky, and Tom M. Folks,
Retrovirus Diseases Branch, Division o f Viral and Rickettsial Diseases
Infection of cells by HIV can result in a period of quiescence or latency, which may 
be obviated by treatment with various inducing agents such as 5-azacytidine. Evi­
dence from our experiments suggests that several CpG sites exist to form a “CpG 
island” within the HIV core enhancer, and block the expression of viral mRNA when 
these sites are methylated. Both viral and cellular trans-acting factors are able to 
overcome this transcriptional block. In addition, such changes in the méthylation 
profile of the long terminal repeat (LTR) can alter the interaction of DNA: protein 
binding, and a new class of binding proteins which recognize the methylated HIV 
LTR is suspected. In these studies, we are developing a direct method of genomic 
sequencing and in vivo footprinting to elucidate the nature of these sites in both 
latent and productive viral states. This technique may be eventually exploited to 
detect viral genomic sequences directly from primary viral isolates.
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MAPPING SURFACE-EXPOSED EPITOPES OF THE CH LAM YD IA  
TR A C H O M A TIS  MAJOR OUTER MEMBRANE PROTEIN.
Jim Newhall, Molecular Epidemiology and Pathogenesis Branch, Division o f Sex­
ually Transmitted Diseases Laboratory Research
The major outer membrane protein (MOMP) of Chlamydia trachomatis functions 
both as a structural protein and as a channel-forming protein through the outer 
membrane. In addition, this protein accounts for over 60% of the outer membrane 
protein mass and is the principal antigenic component at the surface of the organism. 
As such, MOMP represents the main target for potentially neutralizing host immune 
responses. Thus, there is considerable interest in MOMP for the development of 
vaccines to prevent chlamydial disease including trachoma as well as sexually trans­
mitted diseases. The purpose of our current studies is to identify the amino acid 
sequences of MOMP that make up some of the epitopes of this protein that are known 
to give rise to neutralizing antibody. Three separate methods have been used to 
localize MOMP epitopes. In the first, the protein is digested briefly with a protease 
(V8 or chymotrypsin) that cuts the protein into fairly large fragments (>10 kilodal- 
tons). The location of different epitopes on individual fragments can then be deter­
mined by immunoblotting. The second method of mapping utilizes synthetic 
hexapeptides that collectively span known antigenic regions of the protein. By 
screening overlapping peptides, it is possible to locate the primary binding sequence 
of epitope-specific monoclonal antibodies. The third mapping technique uses plas­
mid expression vectors to create hybrid proteins consisting of (3-galactosidase and 
any polypeptide sequences desired. Using these methods we have been able to 
determine the amino acid sequences that make up five different surface-exposed 
epitopes of the chlamydial MOMP. These sequences are currently being used to 
construct immunogens for vaccine testing in animal models.
%NEWER APPROACHES TO IDENTIFICATION OF RESPIRATORY VIRUSES: 
CULTURES, DIRECT DETECTION, PROBES.
John C. Hierholzer, Respiratory and Enterovirus Branch, Division o f Viral and
Rickettsial Diseases
The 1990s have opened with challenging opportunities in the field of viral diagnosis, 
especially rapid viral diagnosis. Changes in our approaches to respiratory virus 
identification are being brought about by problems with monkeys and monkey- 
derived tissue culture, by the expenses incurred in lengthy culturing and routine 
identification tests, and by genetically intermediate strains which defy straightfor­
ward identification. For example, herpes B, Ebola, and simian immunodeficiency 
viruses are adventitious monkey agents that are making the use of tissue products 
from monkeys both unsafe and impractical. As expenses with cell cultures and media 
components multiply, we are substituting enzyme- and time-resolved fluoroimmu- 
noassays in rapid diagnostic formats to circumvent the need for extensive culturing. 
To identify respiratory viruses by their genetic properties, we are developing specific 
DNA primer pairs and DNA probes; genomic sequence analyses of field isolates are 
under way to assist in the refinement of molecular reagents of high specificity and 
sensitivity. Our goals are to employ and develop rapid diagnostic techniques to 
identify whole virus, viral antigens, or viral nucleic acid directly in clinical speci­
mens, to culture only the positive specimens and to minimize culturing to only what 
is needed for preserving the strains for future use.
9
RABIES DIAGNOSTIC REAGENTS PREPARED FROM A RABIES N GENE 
RECOMBINANT EXPRESSED IN BACULOVIRUS.
Frances Reid-Sanden, John W. Sumner, Jean S. Smith, MaKonnen Fekadu, John H. 
Shaddock, and William J. Bellini, Viral and Rickettsial Zoonoses Branch, Division 
o f Viral and Rickettsial Diseases
A gene encoding the nucleoprotein (N) of rabies virus was inserted into the genome 
of the baculovirus Autographa californica nuclear polyhedrosis virus. Recombinant 
gene expression was controlled by the polyhedrin gene promoter. Insect cells 
[Spodoptera frugiperda) infected by a baculovirus recombinant containing the N 
gene insert produced a novel 55-kilodalton protein comparable in size to the rabies N 
protein, as demonstrated by sodium dodecyl sulfate-poly aery lamide gel electrophore­
sis. This new gene product retained the antigenic and immunogenic properties of the 
native viral protein in its ability to react in immunoprécipitation and immunofluores­
cence assays with antirabies antibodies. The baculovirus expression system provides 
a safe, convenient, and inexpensive source of N protein for the production of antise­
rum and adsorbing suspensions for use in rabies diagnoses.
RAPID CONFIRMATION OF L ISTE R IA  M O N O C YTO G EN ES  BY A 
NONISOTOPIC DNA COLONY HYBRIDIZATION METHOD.
Balasubr Swaminathan, Meningitis and Special Pathogens Branch, Division o f
Bacterial Diseases
An oligonucleotide probe was derived from the sequence of a 321-base pair internal 
fragment of msp gene encoding a major secreted polypeptide of Listeria monocyto­
genes. The probe was labeled with digoxigenin using terminal deoxynucleotidyl 
transferase, and its specificity was determined by dot-blot assays. The probe reacted 
with all strains of L. monocytogenes tested (12 of 12 strains representing 5 serotypes). 
It did not react with any other Listeria species or with other gram-positive bacteria 
tested (Brochothrix, Erysipelothrix, Corynebacterium, Rhodococcus, Lactobacillus, 
Leuconostoc, Bacillus, Staphylococcus, and Streptococcus). The nonisotopic DNA 
colony hybridization assay was used for the rapid confirmation of L. monocytogenes 
on Listeria-selective agars that had been streaked with food enrichment cultures. 
Sixty-six food samples were tested by conventional confirmation methods and the 
DNA colony hybridization assay. The sensitivity and specificity of the colony hybrid­
ization assay were 100% and 97%, respectively. The DNA colony hybridization assay 
will be useful for quality control of processed foods, particularly semi-perishable 
foods with limited shelf-life.
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ROLE OF A 60-MDa PLASMID IN THE PATHOGENESIS OF ESCH ERICH IA  
CO LI 0157:H7 DIARRHEA.
Timothy J. Barrett, Istvan Toth, James H. Green, Mitchell L. Cohen, Hella S. 
Rumschlag, and I. Kaye Wachsmuth, Enteric Diseases Branch, Division o f Bacte­
rial Diseases
Escherichia coli strains of serotype 0157:H7 can cause a severe diarrheal illness 
(hemorrhagic colitis) in humans which often results in serious sequelae. These strains 
typically produce Shiga-like toxins and cause attaching and effacing lesions in the 
colons of animal models. Virtually all isolates contain a 60-MDa plasmid which does 
not code for toxin production. We investigated the role of this plasmid in the 
pathogenesis of hemorrhagic colitis. By comparing a plasmid-cured strain with a 
wild-type 0157, we found that the plasmid aided in bacterial adherence. E. coli 
HB101, transformed with the 60-MDa plasmid, caused attaching and effacing lesions 
in human intestinal cell cultures. Electron micrographs revealed electron dense areas 
in the intestinal cells adjacent to bacterial cells; this may represent actin polymeriza­
tion at the site of attachment. The 60-MDa plasmid also mediated the production of 
two proteins identified by enzyme-linked immunosorbent assay (ELISA) and Western 
blot analysis based on absorbed polyclonal antisera. These proteins were found in all 
E. coli 0157:H7 strains and in other serotypes of Shiga-like toxin-producing E. coli; 
traditional EPEC serotypes were also ELISA positive. One or both of these proteins 
may represent a newly recognized virulence factor common to several important 
enteric pathogens. This ELISA should thus be valuable in identifying both patho­
genic E. coli and potentially pathogenic E. coli that are currently unrecognized by 
traditional assays. These proteins may also serve as a basis for future vaccine devel­
opment.
SEROLOGIC DISCRIMINATION OF HTLV I AND HTLV II BY USING AN 
IMMUNODOMINANT EPITOPE OF HUMAN T-LYMPHOTROPHIC VIRUS 
TYPE I.
Renu Lai, Donna Rudolph, Michael Lairmore, Rima Khabbaz, John Coligan, and
Tom Folks, Retrovirus Diseases Branch, Division o f Viral and Rickettsial Diseases
A series of synthetic peptides derived from the gag, pol, and env genes of HTLV I and 
II was selected based upon differences in amino acid sequences and predicted 
secondary structure. A total of 87 serum specimens from HTLV I- and HTLV II- 
infected persons were used to test for the specificity of the assay. Two peptides (P3,E2) 
reacted with both HTLV I- and HTLV II-infected sera (80-90%); the other two 
peptides (Gja.Ej) reacted with 90% of HTLV I-infected sera and 9-11% of those with 
HTLV II infection. In contrast, E5 a peptide derived from envelope region of HTLV I 
reacted with all HTLV I-positive sera and none of the HTLV II sera. Further charac­
terization of E5 epitope demonstrated that it represents a native epitope(s) exposed on 
the HTLV I virus-infected cells. We therefore conclude that the E5 peptide represents 
an immunodominant domain of HTLV I and that E5-based assays distinguish be­
tween infection by these closely related viruses.
li
USE OF 16S rRNA GENE SEQUENCES IN THE DETECTION OF 
CH LAM YD IA  SPECIES BY POLYMERASE CHAIN REACTION.
Patricia Fields and Peter Berdal, Division o f Sexually Transmitted Diseases Labo­
ratory Research and Division o f Bacterial Diseases
16S rRNA gene sequences have been used extensively to assess evolutionary related­
ness among bacteria because these genes are present and serve a similar function in 
all bacteria, and they exhibit both highly conserved and variable sequences. The 
variable regions from these genes have been used as the target for DNA probes, and 
more recently for polymerase chain reaction (PCR) assays that specifically identify or 
detect groups of organisms. We have used sequences from the Chlamydia trachom­
atis and C. pneumoniae 16S rRNA genes as primers in PCR assays that are specific 
for each of these species. The C. pneumoniae primers do not recognize C. trachom­
atis DNA; the C. trachomatis primers do not recognize C. pneumoniae DNA. Addi­
tionally, neither primer pair detected any other bacterial species tested. We have used 
the PCR assays to detect DNA from one to 10 laboratory grown organisms, and to 
detect chlamydial DNA in clinical specimens. The success that we have had using 
16S r RNA genes as the basis for PCR tests for Chlamydia spp. suggests that 16S 
rRNA genes may be a good starting point in the development of PCR assays for other 
bacterial pathogens.
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Centers for Disease Control and 
Agency for Toxic Substances and Disease Registry
POLICY STATEMENT ON 
COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENTS 
AND INTELLECTUAL PROPERTY LICENSING
This Statement sets forth the policies of the Centers for Disease Control (CDC) and the 
Agency for Toxic Substances and Disease Registry (ATSDR) on various aspects of 
cooperative research and intellectual property licensing. These policies apply to the 
negotiation of CDC and ATSDR Cooperative Research and Development Agreements 
(CRADAs). License agreements for intellectual property rights to inventions devel­
oped under a CRADA or through the CDC and ATSDR intramural research programs 
whether negotiated by CDC and ATSDR or by the National Technical Information 
Service on its behalf, will also incorporate these policies. This statement may be 
revised as appropriate.*
The Federal Technology Transfer Act of 1986, (FTTA, 15 U.S.C. at Section 3710), 
Executive Order 12591 of April 10, 1987 orders Federal laboratories to assist univer­
sities and the private sector in broadening our national technology base by moving 
new knowledge from the research laboratory into the development of new products 
and processes. While Federal patent law (35 U.S.C. at Sections 200-212) authorizes 
the licensing of Government-owned patent rights, the FTTA seeks to facilitate tech­
nological collaboration at an earlier stage. Thus the FTTA authorizes Federal labora­
tories to enter into CRADAs, and to agree to grant intellectual property rights in 
advance to collaborators for inventions made in whole or part by Federal employees 
under the CRADA. Besides assisting in the transfer of commercially useful technolo­
gies from Federal laboratories to the market place, CRADAs make outside resources 
more accessible to Federal investigators.
The CDC and ATSDR, agencies of the U.S. Public Health Service (PHS), within the 
Department of Health and Human Services (HHS), are lead Federal agencies for 
prevention and control of disease and disability in the U. S. and throughout the 
world. The CDC and ATSDR primary goals are to prevent disease, illness, injuries, 
and disability before they occur, and to promote health. Under the FTTA, 15 U.S.C. at 
§ 3710(a)2, technology transfer, consistent with mission responsibilities, is also a 
responsibility of each laboratory science and engineering professional. To achieve its 
goals, CDC and ATSDR have developed an interdisciplinary research environment 
and service program that promotes and encourages the free exchange of ideas and 
information.
In order to safeguard the collegiality and integrity of, as well as public confidence in, 
the CDC/ATSDR research programs, the following research and technology transfer 
policies have been adopted.
1. Research Freedom
The CDC and ATSDR investigators generally are free to choose the subject matter of 
their research, consistent with the mission of their Center/Institute/Office (CIO) and 
the research programs of their laboratories. No CRADA or license agreement may 
contravene this freedom.
‘Questions or comments about this statement and requests for updated versions should be directed to 
the CDC Technology Transfer Coordinator at (404) 639-3812.
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2. Research Policy
The CDC and ATSDR research results generally are disseminated freely through 
publication in the scientific literature and presentations at public fora. Brief delays in 
the dissemination of research results may be permitted under a CRADA as necessary 
in order to file corresponding patent or other intellectual property applications. The 
CDC and ATSDR consider the filing of such applications to be an important compo­
nent of its research efforts.
3. Cooperative Research and Development Under a CRADA
As defined by the FTTA, 15 U.S.C. at § 3710a(d)(l), a CRADA means any agreement 
between one or more Federal laboratories and one or more non-Federal parties, 
under which the Government provides personnel, services, facilities, equipment or 
other resources (but not funds), and the non-Federal parties provide funds, person­
nel, services, facilities, equipment or other resources toward the conduct of specified 
research or development efforts. Cooperative research and development activities are 
intended to facilitate the transfer of federally funded research and development for 
use by State and local governments, universities and the private sector, particularly 
small business.
4. CDC and ATSDR CRADAs for Cooperative Research
As adopted by CDC and ATSDR, a CRADA is a standardized agreement intended to 
provide an appropriate legal framework for, and to expedite the approval of, cooper­
ative research and development projects. The use of CRADAs is encouraged for 
cooperative efforts because they permit CDC and ATSDR to accept, retain, and use 
funds, personnel, services, and property from collaborating parties and to provide 
personnel, services, and property to collaborating parties. The CDC and ATSDR may 
permit its investigators to enter into CRADAs with collaborators who will make 
significant intellectual contributions to the research project undertaken or who will 
contribute essential research materials not otherwise reasonably available. While 
CDC and ATSDR welcome contributions to its gift funds for research purposes, it 
does not view CRADAs as a general funding source or a mechanism for sponsored 
research. This approach to implementing the FTTA has been chosen in order to 
maintain the public’s confidence in CDC and ATSDR through maintaining an inde­
pendence from reliance on industry funding.
5. Selection of Collaborators under a CRADA
Collaborators under a CRADA may be suggested by potential collaborators or by 
CDC and ATSDR investigators. Generally, the decision to initiate the approval pro­
cess for a CRADA is made by the involved CDC or ATSDR investigator and labora­
tory chief with the approval of Division and CIO directors. Approval is based on 
scientific considerations and the desire for the public to benefit from the application 
by the private sector of particular CDC and ATSDR research. For some cooperative 
projects, where the development and commercialization potential is more immediate 
relative to the basic research aspects, CDC and ATSDR may seek a collaborator(s) 
which has both scientific expertise and commercialization capabilities. In certain 
areas or research, e.g., where the Government has the intellectual lead or where both 
scientific and commercialization capabilities are deemed essential at the outset, CDC 
and ATSDR may competitively seek a collaborator(s) through Federal Register noti­
fication. The PHS has also developed policy guidelines for ensuring fairness of access 
to PHS laboratories such as CDC in the process of initiating and developing CRADAs. 
Additionally, from time to time CDC and ATSDR may sponsor industry collaboration 
fora to publicize opportunities for collaboration to a wide audience.
6. Proprietary or Confidential Information and Materials
The CDC and ATSDR recognize that an effective collaborative research program may 
require the disclosure of proprietary information to CDC and ATSDR investigators.
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Although agreements to maintain confidentiality are permitted under a CRADA, 
collaborators should limit their disclosure of proprietary information to the amount 
necessary to carry out the research plan of the CRADA. The mutual exchange of 
confidential information, e.g., patient identification data, should be similarly limited. 
The CDC and ATSDR also recognize that cooperative research may require the 
exchange of proprietary research materials. Such materials may be used only for the 
purposes specified in the research plan set forth in the CRADA. All parties to the 
CRADA will agree to keep CRADA research results confidential until they are pub­
lished or presented at a scientific meeting.
7. Treatment of Data and Research Products Produced under a CRADA
The CDC and ATSDR investigator and the collaborator will agree to exchange all data 
and research products developed in the course of research under a CRADA whether 
developed solely by CDC and ATSDR, jointly with the collaborator, or solely by the 
collaborator. In general, tangible research products developed under a CRADA will 
be shared equally by the parties to the CRADA. All parties to a CRADA will be free to 
utilize such data and research products for their own purposes. Data and research 
products developed solely by the collaborator may be designated as proprietary by 
the collaborator when they are wholly separable from the data and research products 
developed jointly with CDC and ATSDR investigators. However, except as may be 
afforded through intellectual property rights that require public disclosure of the 
protected subject matter (e.g., patents), the CDC and ATSDR will not agree to exclude 
others from utilizing or commercializing the data or research products developed 
solely by CDC and ATSDR investigators or jointly with the collaborator under a 
CRADA. Thus, intellectual property which is not patented is not to be afforded trade 
secret status.
8. Ownership of and Licensing of CDC Intellectual Property Rights
Pursuant to the FTTA, 15 U.S.C. at § 3710a(b)(2), a Federal laboratory is authorized to 
own and license patent rights to inventions made in whole or part by its employees 
under a CRADA. The term “invention” is defined at §3703(9) to mean any invention 
or discovery which is or may be patentable or otherwise protected under Title 35 or 
any novel variety of plant which is or may be protectable under the Plant Variety 
Protection Act (PVPA), 7 U.S.C. § 2321 et seq. The patent law, 35 U.S.C. § 207, 
authorizes the ownership and licensing of intramural inventions. Executive Order 
12591 at § 1(b)(1)(B) further authorizes the transfer of Government intellectual prop­
erty rights. Although the FTTA speaks broadly of the transfer of "technology,” CDC 
and ATSDR do not have statutory authority to license (or to agree to limit dissemi­
nation) of technology developed in whole or part by their investigators under a 
CRADA unless a patent, PVPA certificate or other intellectual property application 
has been filed for that technology. The CDC and ATSDR will retain the Government 
ownership interest in, but license rights to, all intellectual property rights to inven­
tions developed solely by their investigators through intramural research or devel­
oped in whole or in part under a CRADA.
9. General Licensing Policy
The CDC and ATSDR recognize that under the FTTA and the patent licensing law to 
which it refers, Congress and the President have chosen to utilize the patent system as 
the primary mechanism for transferring Government inventions to the private sector. 
The importance of patents to commercialization in the biomedical field is further 
reflected by the Drug Price Competition and Patent Term Restoration Act of 1984 
(Pub. L. 98-417). A fundamental principle of the patent system is that the owner of a 
patent has a time-limited “right to exclude others from making, using, or selling the 
[patented] invention.” The reason for such a period of exclusivity is to encourage 
industry to invest the resources necessary to bring an invention from the discovery 
stage through subsequent development, clinical trials, regulatory approvals, and 
ultimately into commercial production. The CDC and ATSDR accordingly are willing
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to grant exclusive commercialization licenses under their patent or other intellectual 
property rights in cases where substantial additional risks, time and costs must be 
undertaken by a licensee prior to commercialization. Under a CRADA, CDC and 
ATSDR are also willing to agree to grant exclusive commercialization licenses in 
advance to collaborators. The CDC and ATSDR will attempt, however, to license their 
intramural inventions nonexclusively in cases where an invention reflects a relatively 
more advanced stage in its commercial development, e.g., when a CDC and ATSDR 
investigator invents a patentable new therapeutic use for a known and FDA approved 
compound.
Federal laboratories are authorized to negotiate license agreements for Government- 
owned patent rights in intramural inventions pursuant to 35 U.S.C. § 207 ~ Although 
§ 207 does not apply to intellectual property license agreements authorized by the 
FTTA for inventions made under a CRADA, CDC and ATSDR have adopted the 
following approach of § 207 for all license agreements:
Each Federal Agency [may] . . . grant nonexclusive, exclusive, 
or partially exclusive licenses under federally owned patent 
applications, patents, or other forms o f protection . . .  on such 
terms and conditions . . .  as determined appropriate in the 
public interest.
The CDC and ATSDR have determined it to be appropriate and in the public interest 
to grant nonexclusive research licenses and either exclusive or nonexclusive com­
mercialization licenses to HHS owned intellectual property rights according to the 
plan discussed below.
10. Government Invention Rights
For inventions developed wholly by CDC and ATSDR investigators or jointly with a 
collaborator under a CRADA, CDC and ATSDR are required by the FTTA at 15 U.S.C. 
§ 3710a(b)(2) to retain at least a nonexclusive, irrevocable, paid-up license to practice 
the invention or to have the invention practiced throughout the world by or on behalf 
of the U.S. Government. When granting exclusive or partially exclusive licenses to 
CDC and ATSDR intramural inventions, 35 U.S.C. § 208, as implemented by 37 C.F.R. 
§ 404.7(2)(i), requires the reservation of similar Government rights. The CDC and 
ATSDR will not assert an ownership right in inventions made solely by a collaborator 
under a CRADA, but will require the grant of a research license, as described below, 
to the Government for inventions made wholly by collaborator under a CRADA.
11. Research Licenses
The CDC and ATSDR will reserve the right under any CRADA and intellectual 
property license to grant nonexclusive licenses to make and to use such property, for 
purposes of research involving the invention itself and not for purposes of commer­
cial manufacture or in lieu of purchase as a commercial product for use in other 
research. The purpose of the research license is to facilitate basic academic research. 
The CDC and ATSDR intend to consult with any involved commercialization licens- 
ee(s) before granting research licenses to commercial entities. The grant of any 
research license hereunder does not permit CDC and ATSDR to grant any license to 
third parties to use the invention for any commercial purpose.
12. Commercialization Licenses
The CDC and ATSDR are willing to consider requests for nonexclusive or exclusive 
commercialization licenses to intellectual property rights to inventions developed 
under a CRADA or in the course of intramural research pursuant to applicable 
statutes and regulations. Under a CRADA, CDC and ATSDR generally will grant a 
time-limited option to negotiate, in good faith, the terms of a license that fairly reflects 
the relative contributions of the parties, the risks incurred by the collaborator and the 
costs of subsequent research and development needed to bring the results of CRADA 
research to the marketplace. The CDC and ATSDR consider the drafting of a model
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invention license to serve as the starting point for license negotiations. It is contem­
plated further that such a model will reduce negotiations essentially to matters of 
execution fees royalty rates and minimum annual royalties. Royalty rates will be 
based on product sales and the rates conventionally granted in the field identified in 
the CRADA’s research plan for inventions with reasonably similar commercial po­
tential. Royalty rates generally will not exceed a rate within the range of 5-8 percent 
for exclusive commercialization licenses. Contingent royalty schemes based on, e.g., 
patent issuance or nonissuance, and clauses treating the stacking of royalties or 
packaging of other inventions developed under the CRADA may be provided. Exclu­
sive licensees will be expected to reimburse CDC and ATSDR for intellectual property 
related expenses, and may be permitted to offset such reimbursement against future 
product royalties.
13. Nonexclusive Commercialization Licenses
Unless a request for exclusive commercialization license is made under a CRADA or 
submitted for an intramural invention, CDC and ATSDR will attempt to license their 
inventions nonexclusively. Such nonexclusive licenses generally will follow the 
guidelines of 37 C.F.R. Part 404.
14. Exclusive Commercialization Licenses
The CDC and ATSDR exclusive commercialization requires the submission by a 
prospective licensee of an acceptable development and commercialization plan as 
described by 35 U.S.C. § 209(a) and subsequent, periodic reports on utilization of the 
invention as described by § 209(f)(1). All such plans and reports will be treated in 
confidence and as privileged from disclosure under the Freedom of Information Act. 
Modification provisions as described by § 209(f)(2)-(4) may apply. In appropriate 
cases, CDC and ATSDR may also reserve the right to grant separate exclusive com­
mercialization licenses in various fields of use. The remaining provisions of 35 U.S.C. 
§§ 200-212 will also apply to licenses to CDC and ATSDR intramural inventions. The 
CDC and ATSDR also consider the following provisions for exclusive commercializa­
tion licenses to be necessary and appropriate in the public interest:(stop)
(i) the exclusive licensee must pledge its reasonable best efforts to commercialize 
a licensed invention and the development and commercialization plan mentioned 
above may serve as the measure of such efforts;
(ii) the CDC and ATSDR shall have the right, after notice and opportunity to cure, 
to terminate or render nonexclusive any license granted: (1) if the licensee is not 
reasonably engaged in research, development, clinical trials, manufacturing, mar­
keting, sublicensing, or other activities reasonably necessary to the expeditious 
commercial dissemination of the licensed invention; or (2) when the licensee 
cannot reasonably satisfy unmet health and safety needs;
(iii) in order to maximize the commercialization of the licensed invention in other 
fields of use not utilized by the exclusive licensee through ongoing development, 
manufacturing or sub licensing, CDC and ATSDR reserve the right to require the 
licensee to grant sublicenses to responsible applicants, on reasonable terms, in 
such other fields of use unless the licensee can reasonably demonstrate that such 
a sublicense would be contrary to sound and reasonable business practice and the 
granting of the sublicense would not materially increase the availability to the 
public of the licensed invention; and
(iv) exclusive licensees to HHS inventions, whether developed under a CRADA or 
through intramural research, must agree to not unreasonably deny requests for 
sublicense or cross license rights from future CRADA collaborators when the 
possibility of acquiring such derivative rights is necessary in order to permit a 
proposed cooperative research project with CDC and ATSDR to go forward, and 
the exclusive licensee has been given a reasonable opportunity to join as a party 
to the proposed CRADA. The grant of any sublicense or cross license rights
17
hereunder does not grant future CRADA collaborators a license to use or CDC and 
ATSDR the right to grant to future CRADA collaborators a license to use any 
inventions of the instant CRADA for any commercial purpose.
15. Compliance under CRADAs with Other Policies
For research conducted pursuant to a CRADA, collaborators must agree to comply 
with PHS, CDC and ATSDR policies and guidelines concerning, e.g., human subjects 
research, the use of research animals, recombinant DNA and other policy statements 
as may be promulgated from time to time.
16. Pricing
HHS has responsibility for funding basic biomedical research, for funding medical 
treatment through programs such as medicare and medicaid, for providing direct 
medical care, and more generally, for protecting the health and safety of the public. 
Because of these responsibilities, and the public investment in the research that 
contributes to a product licensed under a CRADA, HHS has a concern that there be a 
reasonable relationship between the pricing of a licensed product, the public invest­
ment in the product, and the health and safety needs of the public.
17. Waivers
The CDC and ATSDR will consider requests to modify any of the foregoing policies 
in special cases where public health exigencies or commercial situations warrant 
such a modification. Modifications dealing with business terms such as royalties are 
not decided by the CDC and ATSDR investigators and should be discussed with the 
appropriate CDC and ATSDR technology management personnel.
18. Special Consideration and Preference under a CRADA
The CDC and ATSDR will give special consideration to entering into CRADAs with 
small business firms and consortia involving small business firms; and will give 
preference to business units located in the United States which agree to manufacture 
substantially in the United States products which embody inventions developed in 
the course of research under CRADAs.
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